Hepatocellular carcinoma (HCC) generally develops as a ... The identifiable population at risk makes screening a realistic possibility, and liver imaging is recommended every 6 months for patients ...

In 2005, 1002 (39%) patients, with a mean age of 66.7 ± 8.6 years, responded to this follow-up screening, including 461 (aged 68.3 ± 8.7 years) males and 541 (65.3 ± 8.2 years) females.

Hepatocellular carcinoma, a type of liver cancer, is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths. Screening efforts for this cancer focus on ...

China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...

Disparities in liver cancer risk and outcomes in the LGBTQ community: A literature review. Non-contrast MRI as a surveillance tool for recurrent hepatocellular carcinoma after curative treatment: A ...

Investigator Award has been awarded to two surgeon-scientists at the National Cancer Centre Singapore (NCCS) to pursue novel research in liver cancer and head and neck cancers. Globally, liver cancer ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Fujifilm Middle East and Africa part of the globally renowned Fujifilm Corporation is participating at Arab Health 2025 taking place between 27th a ...